Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of BCD-178 (Pertuzumab Biosimilar) vs Perjeta in Healthy Male Volunteers
NCT05738993Phase 1Unknown
- Sponsor
- BIOCAD
- Start
- Aug 2022
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BCD-178 in breast cancer (2 arms), sponsored by BIOCAD. Primary endpoint: Area under the concentration-time curve from time zero to infinity at Day 91. Status: unknown.
02
Drugs
BCD-178
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05738993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05738993.